Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Exclusion Criteria

• •Forms of psoriasis other than chronic plaque
• •Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers, calcium channel inhibitors)
• •Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV therapy)
• •Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL17A or IL-17RA receptors
• •Use of other investigational drugs within 30 days prior to study entry, or within a period of 5 half-lives of the investigational treatment, whichever is longer
• •Active, ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab
• •Active system infections (with the exception of the common cold) during the two weeks prior to starting study treatment